T h e ne w e ngl a nd jou r na l o f m e dic i ne n engl j med 362;18 nejm.org may 6, 2010 1676 N onalcoholic steatohepatitis is a common liver disease that is character ized histologically by hepatic steatosis, lobular inflammation, and hepatocellular balloon ing 1, 2 ; it can progress to cirrhosis in up to 15% of patients. 3, 4 There is currently no therapy that is of proven benefit for nonalcoholic steatohepati tis. The disease is closely associated with insulin resistance and features of the metabolic syndrome such as obesity, hypertriglyceridemia, and type 2 diabetes. 5, 6 In addition to insulin resistance, oxi dative stress has been implicated as a key factor contributing to hepatic injury in patients with nonalcoholic steatohepatitis. 6, 7 Thus, both insulin resistance and oxidative stress are attractive tar gets for therapy in patients with this disease.
Several pilot studies have provided evidence that insulin sensitizers such as thiazolidinediones and antioxidants such as vitamin E improve clinical and histologic features of nonalcoholic steato hepatitis. [8] [9] [10] [11] [12] [13] [14] The medical evidence of a benefit, however, is limited, because these studies had small samples and were performed at single cen ters. Moreover, a recent multicenter trial showed a reduction in hepatic steatosis but no improve ment in markers of cell injury after a year of rosiglitazone therapy. 15 The value of these drugs remains uncertain.
The Nonalcoholic Steatohepatitis Clinical Re search Network (NASH CRN) was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to address unmet research needs in the field. As a part of this man date, the NASH CRN conducted the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steato hepatitis (PIVENS) trial, a phase 3, multicenter, randomized, placebocontrolled, doubleblind clinical trial of pioglitazone or vitamin E for the treatment of adults without diabetes who had biopsyconfirmed nonalcoholic steatohepatitis.
Me thods

Study Oversight
The PIVENS protocol and consent forms were de signed by a subcommittee and approved by the steering committee of the CRN (see the Appen dix). The study was approved by the review board at each participating center, and all subjects gave written informed consent. The study was con ducted by site investigators, and data were gath ered by specifically trained personnel. The data were analyzed at the data coordinating center and were reviewed by both the investigators and an independent data and safety monitoring board. The manuscript was written by a CRN subcom mittee and approved by the members of the steer ing committee, who assume responsibility for the integrity of the data and the overall content of the manuscript.
Study Design
The trial design and rationale for the PIVENS trial have been described previously. 16 This trial fo cused on adults without diabetes who had nonal coholic steatohepatitis. Adults with diabetes were excluded because it was unclear whether they would have the same responses to therapy as would adults without diabetes and because it was possible that changes in antidiabetic therapy might confound the analysis of data both from subjects with diabetes and from those without diabetes. All subjects underwent a liver biopsy within 6 months before randomization.
Steatohepatitis was categorized as absent, pos sible, or definite. 17 Disease activity was assessed with the use of the nonalcoholic fatty liver disease activity score, which is based on a standardized grading system for steatosis (on a scale of 0 to 3), lobular inflammation (on a scale of 0 to 3), and hepatocellular ballooning (on a scale of 0 to 2), with higher scores indicating increasing severity). 17 The specific inclusion criteria were definite or possible steatohepatitis with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. A score of at least 1 for hepatocellular ballooning was required in all cases. Although eligibility was determined by the pathologist at each site from an assessment of tissue sections prepared locally, the final analysis was based on review by a pathology committee of deeper cuts, prepared centrally, from the biopsy specimens obtained at baseline and at the end of treatment. Members of the pathology committee who performed the final analysis were unaware of the studygroup assignments.
Exclusion criteria were alcohol consumption of more than 20 g per day in the case of women and more than 30 g per day in the case of men for at least 3 consecutive months during the previous 5 years, as assessed with the use of the Lifetime Drinking History questionnaire of Skinner et al. 18 and the selfadministered Alcohol Use and Disor ders Identification Test (AUDIT). 19 Subjects were also excluded if they had cirrhosis, hepatitis C or other liver diseases, or heart failure (New York Heart Association class II to IV), or if they were receiving drugs known to cause steatohepatitis. Both at the initial evaluation and at the com pletion of treatment 96 weeks later, subjects un derwent an assessment of body weight, height, and waist and hip circumferences, and blood samples were obtained for routine biochemical tests and assessment of fasting levels of lipids, glucose, and insulin. Body composition was as sessed with the use of dualenergy xray absorp tiometry. The Medical Outcomes Study 36Item ShortForm Health Survey (SF36) was adminis tered for the assessment of quality of life.
Randomization and Treatment Groups
Subjects who met all eligibility criteria and pro vided written informed consent were randomly assigned to one of three groups for 96 weeks of study treatment: a group receiving pioglitazone (at a dose of 30 mg once daily) and a vitamin E-like placebo (once daily), a group receiving vi tamin E (800 IU, natural form, once daily) and a pioglitazonelike placebo (once daily); or a group receiving a pioglitazonelike placebo (once daily) and a vitamin E-like placebo (once daily). The 30mg pioglitazone tablets (Actos) and similar appearing placebo tablets were provided by Take da Pharmaceuticals North America under a col laborative research and development agreement with the NIDDK. The 800IU liquid softgelatin capsules of RRRαtocopherol (formerly known as dαtocopherol) vitamin E (Nature Made) and similarappearing placebo softgelatin capsules were provided by Pharmavite under a clinical trial agreement with the NIDDK. Both Takeda and Pharmavite provided comments regarding the study design but were not involved in the writing of the protocol, the conduct of the trial, the decisionmaking with respect to the trial, or the analy sis of the data. Both companies were shown a draft of the manuscript 30 days before it was submitted for publication but were not in volved in the preparation of the manuscript. The doses were selected on the basis of previous phase 2 studies. 9,13
Follow-up Visits
After randomization, subjects were followed ac cording to a predetermined schedule for assess ment of the safety and tolerability of the study drugs. Subjects were discouraged from adding other drugs that are used for nonalcoholic steato hepatitis to their regimen. All subjects were given a standardized set of pragmatic recommendations about lifestyle changes and diet. A liver biopsy was performed 96 weeks after randomization, after which the study drugs were discontinued. Subjects were then followed for an additional 24 weeks.
Primary and Secondary Outcomes
The primary outcome was an improvement in his tologic findings, which required an improvement by 1 or more points in the hepatocellular balloon ing score; no increase in the fibrosis score; and either a decrease in the activity score for nonalco holic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1point decrease in either the lobu lar inflammation or steatosis score.
Secondary outcomes included changes in the overall activity score for nonalcoholic fatty liver disease, as well as in individual component scores for steatosis, lobular inflammation, hepatocel lular ballooning, and fibrosis, and changes in se rum aminotransferase levels, anthropometric mea sures, and insulin resistance and lipid profiles. An additional secondary outcome was the change in healthrelated quality of life from baseline to the end of treatment, as assessed with the use of the SF36.
Statistical Analysis
The primary analysis was an intentiontotreat analysis in which the proportions of subjects in each activetreatment group (pioglitazone and vi tamin E) in whom there was improvement in non alcoholic steatohepatitis were compared with the proportion of subjects in the placebo group in whom there was improvement. Comparisons were made with the use of the Mantel-Haenszel chi square test, stratified according to clinical site. Subjects who did not undergo an endoftreatment biopsy were classified as not having had improve ment. Given the fact that there were two planned primary comparisons, Bonferroniadjusted P val ues of less than 0.025 were considered to indicate statistical significance. The number of subjects who would need to be treated to achieve histo logic improvement in one patient was calculated for the vitamin E and pioglitazone treatments. We analyzed secondary outcomes with the use of Fisher's exact test for binary outcomes and analy sisofcovariance models for continuous outcomes, regressing change from baseline to 96 weeks on treatment group and baseline value of the out come variable in order to adjust comparisons of mean changes in secondary outcomes for the base line value of the outcome variable. The planned sample size was 240 subjects, with equal assignment to each of the three study groups (80 per group). We estimated that with this sample size, the study would have 90% power to detect an absolute difference in the rate of improvement in nonalcoholic steatohepatitis of 26 percentage points, with a twosided type 1 error of 0.025. 16 An independent data and safety monitoring board appointed by the NIDDK monitored the results semiannually; O'Brien-Fleming statistical stop ping guidelines were used, with one interim analysis for efficacy performed midway through the trial.
R esult s
Study Subjects
Subjects were enrolled in the trial between Janu ary 2005 and January 2007 and were treated and followed for 96 weeks (Fig. 1 ). Of the 247 sub jects who underwent randomization, 83 were as signed to receive placebo, 84 were assigned to re ceive vitamin E, and 80 were assigned to receive pioglitazone. The three groups were well matched with respect to demographic characteristics, clini cal and laboratory data, and activity scores for nonalcoholic fatty liver disease (Table 1) . However, according to the planned, blinded, central analy sis of liverbiopsy specimens, 17% of the subjects in the placebo group, 18% of those in the vita min E group, and 28% of those in the pioglitazone group did not have hepatocellular ballooning on assessment of their initial biopsy specimen.
Primary Outcome
A total of 90% of the subjects underwent an end oftreatment liver biopsy at 96 weeks. Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001; number needed to treat, 4.2), but the comparison of pioglitazone therapy with placebo did not reach the prespecified 0.025 level of sig nificance for the primary outcome (34% vs. 19%, P = 0.04; number needed to treat, 6.9) ( Table 2 ).
Given the subjectivity of histologic analysis, several sensitivity analyses were performed. If a finding of no worsening (rather than improve ment) of hepatocellular ballooning was used as a criterion in the outcome measure, both active drugs were significantly associated with an im provement in histologic features of nonalcoholic steatohepatitis, as compared with placebo (pla cebo vs. vitamin E: 25% vs. 51% improvement, P<0.001; placebo vs. pioglitazone: 25% vs. 48%, P = 0.003). When subjects who did not have hepa tocellular ballooning initially, as assessed by cen tral review, were excluded from the analyses, both active drug groups were associated with a signifi cant improvement in histologic findings (placebo vs. vitamin E: 23% vs. 52% improvement, P<0.001; placebo vs. pioglitazone: 23% vs. 47%, P = 0.002). An analysis of baseline factors to identify char acteristics associated with a histologic response to either active treatment did not reveal any sig nificant findings, and the data were consistent across all subgroups that were analyzed (Table 10 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
Secondary Outcomes
Histologic Features
As compared with the placebo group, both ac tivetreatment groups had a significant reduction in steatosis, lobular inflammation ( Fig. 1 in the Supplementary Appendix), and the activity score for nonalcoholic fatty liver disease (Table 2) . Al though scores for hepatocellular ballooning were improved with vitamin E and with pioglitazone, only the improvement with vitamin E was signifi cant (P = 0.01). Fibrosis scores were not signifi cantly improved with either active treatment. Ste atohepatitis resolved in a greater proportion of subjects receiving either vitamin E or pioglitazone than in those receiving placebo, but the difference was significant only for those receiving pioglita zone (P = 0.001) ( Table 2) .
Serum Enzyme Levels and Liver Test Results
There was an early and highly significant decrease in mean aspartate aminotransferase and alanine aminotransferase levels among subjects receiving vitamin E and among subjects receiving pioglita zone (Fig. 2) . These changes occurred in the first 24 weeks and were sustained throughout the pe riod in which the subjects were receiving treat ment. Serum concentrations of alkaline phos pha tase and γglutamyl transpeptidase also improved in the two activedrug groups, but bilirubin lev els did not change significantly.
Body Weight, Insulin Resistance, and Quality of Life
There was a significant improvement in insulin resistance only in the pioglitazone group, but that group was also the only group that had a signifi cant mean weight gain (a mean increase of 4.7 kg at week 96, P<0.001 for the comparison with pla cebo) ( Table 3) . These changes were noted by week 24, and the weight gain progressed over the course of the study. Although insulin resistance returned to the baseline value after discontinuation of pio glitazone, the associated weight gain was not re versed. Changes in quality of life, as assessed by the scores for both the mental and physical com ponents of the SF36, did not differ significantly between the vitamin E group or the pio glit azone group and the placebo group (Table 3) .
Adverse Events
With the exception of weight gain, the overall dis tribution of individual adverse events did not dif fer significantly across the study groups. There were 19 severe adverse events -10 in the place bo group, 7 in the vitamin E group, and 2 in the pioglitazone group (see Table 3 taking placebo (12 events), those taking vitamin E (12), and those taking pioglitazone (10) . No cases of congestive heart failure were reported. The fre quency of bone fractures was also similar across study groups: five in the placebo group, three in the vitamin E group, and three in the pioglita zone group. During the 96 weeks of the study, diabetes developed in four subjects who were re ceiving vitamin E but in none of the subjects who were receiving placebo or pioglitazone (P = 0.12 for the comparison of vitamin E with placebo). Symptoms and signs of cirrhosis (thrombocytope nia, anasarca, and hyperbilirubinemia) developed in one patient in the vitamin E group who had had bridging hepatic fibrosis at entry, and that patient died of sepsis. No cases of serious hepa totoxicity requiring permanent discontinuation of the study drug were reported.
Discussion
The assessment of therapeutic agents for nonal coholic steatohepatitis is a complex process. Be cause there are no validated biomarkers of response * P values were calculated with the use of the Mantel-Haenszel chi-square test, stratified according to clinic, for the primary outcome; Fisher's exact test for the binary secondary outcomes; and analysis-of-covariance models, regressing change from baseline to 96 weeks on treatment group and baseline value of the outcome, for secondary outcome scores. † The primary outcome was an improvement in histologic findings, which required improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 points or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score. A total of 11 subjects in the placebo group, 4 in the vitamin E group, and 10 in the pioglitazone group had missing histologic data at week 96, and the results for these subjects were imputed as a lack of improvement. The NAFLD activity score was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). ‡ Fibrosis was assessed on a scale of 0 to 4, with higher scores indicating more severe fibrosis. to treatment, one must rely on histologic assess ment of a liverbiopsy specimen for this purpose. The activity score for nonalcoholic fatty liver dis ease quantifies the severity of steatosis, hepato cellular ballooning, and inflammation -the key histologic components of the disease. 17 A decrease in their severity occurs with amelioration of the disease; however, the severity of these components (especially hepatic steatosis) may also decrease with progression of fibrosis to cirrhosis. 20, 21 To develop an outcome that was both quanti fiable and clinically relevant, the requirements of an improvement in ballooning and no worsening of fibrosis were added to the requirement of a decrease in the nonalcoholic fatty liver disease activity score for the primary outcome. This makes it likely that the observed improvements with vi tamin E are both statistically and clinically sig nificant. These improvements are also concordant with those in previous small, pilot trials. 12, 13 These data cannot, however, be generalized to patients with diabetes or to those with cirrhosis, and ad ditional clinical trials both to confirm these find ings and to determine the generalizability of the data are warranted.
The New England
Although pioglitazone did not meet the pre specified significance level for the primary out come, it was associated with highly significant reductions in steatosis, inflammation, and hepato cellular ballooning, as well as with improvements in insulin resistance and liverenzyme levels ( Table  2 and Fig. 2 ). It also led to the resolution of steatohepatitis in a significant proportion of subjects. One possible reason for the failure to achieve the primary outcome with pioglitazone therapy, even though it significantly improved in dividual features of nonalcoholic steatohepatitis, is that more subjects in the pioglitazone group than in the vitamin E and placebo groups were classified as not having had ballooning, on the basis of the planned central review of deeper cuts of baseline biopsy specimens, and a reduction in Mean values are shown for changes from baseline (the value at follow-up minus the baseline value) in alanine aminotransferase levels, aspartate aminotransferase levels, insulin resistance, and weight among the 83 subjects in the placebo group, 84 subjects in the vitamin E group, and 80 subjects in the pioglitazone group. All available data were included in the calculation of means; data were missing for less than 10% of subjects. ballooning was one of the criteria for the primary outcome. The discrepancies between the results of liver histologic assessments that were performed locally to determine eligibility and the results of assessments of deeper cuts of the same tissue block that were performed centrally to determine histologic baseline and outcome measures for use in the study analyses may have been due to inter observer variability, variable distribution of his tologic findings in the different tissue sections, or a potential bias due to the unblinded nature of the local pathological review to determine eli gibility. [22] [23] [24] It is important not to overinterpret the data on adverse events in this trial because the study was not powered to test any safetyrelated hypoth eses. The risk of bone fracture was not increased with pioglitazone 25 ; however, the number of post menopausal women included in the trial was too small to assess any potential effect. Although dia betes developed in subjects in the vitamin E group but not in subjects in the other two groups, only four subjects were affected, and this number is smaller than the number that would be expected in this patient population. Finally, cardiovascu lar events occurred with equal frequency in all three study groups, but, again, the trial was much too small to detect meaningful differences in the incidence of cardiovascular events.
Enthusiasm for the potential benefits of pio glitazone and vitamin E must be tempered by the finding that there was an improvement in histo logic features in only 34% of the subjects who received pioglitazone and 43% of those who re ceived vitamin E, and steatohepatitis resolved in only 47% and 36% of the subjects in those two groups, respectively. Neither agent was associated with a significant improvement in the mean fi brosis score after 96 weeks of treatment. There was also no significant reduction in portal in flammation, which has been linked to advanced disease. 4, 26 Given the certainty of relapse after discontinuation of the drug, it is likely that which ever drug is prescribed for nonalcoholic steato hepatitis, it will need to be taken indefinitely. 13, 27 The weight gain among the subjects receiving pioglitazone -which did not resolve after dis continuation of the drug -also detracts from its longterm usefulness. The unknown longterm potential for adverse events with vitamin E and pioglitazone therapies must be factored into the decision about whether to use these agents. 25, 28, 29 The decision about which specific therapy to use for the treatment of nonalcoholic steatohepa titis should include a consideration of both the efficacy and the toxic effects of the therapy as compared with those of other available therapies. Preliminary studies provide a rationale for the use of lifestyle intervention, bariatric surgery, phle botomy, and a variety of drugs. However, the usefulness of each of these therapeutic options has not been validated in rigorously performed, randomized, controlled trials. Our study provides such evidence for vitamin E and pioglitazone; however, this trial was not designed to compare vitamin E with pioglitazone, and no conclusions can be drawn about their relative efficacy.
In summary, the results of this trial of pioglit azone and vitamin E for the treatment of nonal coholic steatohepatitis in adults without diabetes showed that vitamin E was superior to placebo and suggested that pioglitazone may also have ef ficacy. Although only subjects who received vita min E met the criteria for the prespecified primary outcome measure, subjects who received pioglit azone had significant improvement in other im portant histologic features of nonalcoholic steato hepatitis.
